Your browser doesn't support javascript.
Feasibility and first results of the 'Trials-within-Cohorts' (TwiCs) design in patients undergoing radiotherapy for lung cancer.
Tomassen, Mathijs L; Damen, Pim J J; Verkooijen, Helena M; Peters, Max; van der Stap, Janneke; van Lindert, Anne S R; Verhoeff, Joost J C; van Rossum, Peter S N.
  • Tomassen ML; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Damen PJJ; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Verkooijen HM; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Peters M; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • van der Stap J; Department of Pulmonology, University Medical Center Utrecht, The Netherlands.
  • van Lindert ASR; Department of Pulmonology, University Medical Center Utrecht, The Netherlands.
  • Verhoeff JJC; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • van Rossum PSN; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Acta Oncol ; 62(3): 237-244, 2023 Mar.
Article in English | MEDLINE | ID: covidwho-2284275
ABSTRACT

Background:

'Trials-within-Cohorts' (TwiCs), previously known as 'cohort multiple randomized controlled trials' is a pragmatic trial design, supporting an efficient and representative recruitment of patients for (future) trials. To our knowledge, the 'COhort for Lung cancer Outcome Reporting and trial inclusion' (COLOR) is the first TwiCs in lung cancer patients. In this study we aimed to assess the feasibility and first year results of COLOR.Material and

Methods:

All patients diagnosed with lung cancer referred to the Radiotherapy department were eligible to participate in the ongoing prospective COLOR study. At inclusion, written informed consent was requested for use of patient data, participation in patient-reported outcomes (PROs), and willingness to participate in (future) trials. Feasibility was studied by assessing participation and comparing baseline PROs to EORTC reference values. First-year results of PROs at baseline and 3 months after inclusion were evaluated separately for stereotactic body radiotherapy (SBRT) and conventional radiotherapy patients.

Results:

Of the 338 eligible patients between July 2020 and July 2021, 169 (50%) participated. Among these, 127 (75%) gave informed consent to PROs participation and 110 (65%) were willing to participate in (future) trials. The inclusion percentage dropped from 77% to 33% when the information procedure was switched from in-person to by phone (due to COVID-19 pandemic measures). Baseline PROs for physical and cognitive functioning were comparable in COLOR patients compared to the EORTC reference values. No significant changes in PROs were observed 3 months after inclusion, except for a slight increase in pain scores in the SBRT group (n = 97).

Conclusions:

The TwiCs-design appears feasible in lung cancer patients with fair participation rates (although negatively impacted by the COVID-19 pandemic). With a planned expansion to other centers, the COLOR-study is expected to enable multiple (randomized) evaluations of experimental interventions with important advantages for recruitment, generalizability, and long-term outcome data collection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Lung Neoplasms Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Acta Oncol Journal subject: Neoplasms Year: 2023 Document Type: Article Affiliation country: 0284186X.2023.2183778

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Lung Neoplasms Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Acta Oncol Journal subject: Neoplasms Year: 2023 Document Type: Article Affiliation country: 0284186X.2023.2183778